Aimei Health Files Definitive Proxy Materials

TL;DR

Aimei Health dropped proxy docs, no fee. Standard shareholder stuff.

AI Summary

Aimei Health Technology Co., Ltd. filed a DEFA14A on January 30, 2025, indicating it is providing definitive additional materials related to its proxy statement. The filing does not require a fee, as indicated by the company's selection of 'No fee required.' The company's principal executive offices are located at 10 East 53rd Street, Suite 3001, New York, NY 10022.

Why It Matters

This filing is a standard regulatory step for public companies to provide shareholders with important information and voting materials, ensuring transparency in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) for a public company, not indicating any immediate financial or operational risks.

Key Players & Entities

• Aimei Health Technology Co., Ltd (company) — Registrant
• 10 East 53rd Street, Suite 3001, New York, NY 10022 (location) — Business and Mail Address

FAQ

Key Financial Figures

• $60,000 — Proxy Statement from an amount equal to $60,000 for all outstanding public shares (for
• $150,000 — onthly extension) to an amount equal to $150,000 for all outstanding public shares (for
• $0.033 — its initial business combination, from $0.033 per Public Share (as defined below) (fo
• $50,000 — of taxes payable or owed and less up to $50,000 of interest that may be released to the

Filing Documents

• formdefa14a.htm (DEFA14A) — 58KB
• proxy_001.jpg (GRAPHIC) — 502KB
• proxy_002.jpg (GRAPHIC) — 373KB
• 0001493152-25-004227.txt ( ) — 1265KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant   Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 AIMEI HEALTH TECHNOLOGY CO., LTD (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. EXPLANATORY NOTE Aimei Health Technology Co., Ltd (“ Aimei Health ,” “ Company ,” “ we ,” “ us ” or “ our ”) is filing these definitive additional proxy materials with respect to the definitive proxy statement filed by Aimei Health with the U.S. Securities and Exchange Commission (the “ SEC ”) on January 21, 2025 (the “ Definitive Proxy Statement ”), for the extraordinary general meeting of shareholders of Aimei Health (the “ Extraordinary General Meeting ”) scheduled for February 4, 2025, in order to increase the amount of the proposed monthly extension fee described in the Definitive Proxy Statement from an amount equal to $60,000 for all outstanding public shares (for each monthly extension) to an amount equal to $150,000 for all outstanding public shares (for each monthly extension). All other information in the Definitive Proxy Statement remains unchanged. SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT The following disclosures should be read in conjunction with the disclosures contained in the Definitive Proxy Statement, which should be read in its entirety. To the extent the information set forth herein differs from or updates information contained in the Definitive Proxy Statement, the information set forth herein shall supersede or supplement the information in the Definitive Proxy Statement. The terms used below, unless otherwise defined, have the meanings set forth in the Definitive Proxy Statement. SUPPLEMENT NO. 1, DATED JANUARY 30, 2025 (TO THE DEFINITIVE PROXY STATEMENT OF AIMEI HEALTH TECHNOLOGY CO., LTD, DATED JANUARY 21, 2025) SUPPLEMENT TO THE PROXY STATEMENT This supplement to the Definitive Proxy Statement (the “ Supplement ”), supplements, updates and amends the Definitive Proxy with the Definitive Proxy Statement, which should be read in its entirety. 1. The second subsection of the third paragraph on the first page of the Notice of Extraordinary General Meeting of Shareholders is hereby amended and restated as follows: 2. Proposal 2 – To approve an amendment to the Investment Management Trust Agreement dated December 1, 2023 (the “ Trust Agreement ”), entered into by and between Continental Stock Transfer & Trust Company, as trustee (the “ Trustee ”) and the Company governing the trust account established in connection with the Company’s initial public offering (“ IPO ”), to amend the amount of funds to be deposited by our sponsor, Aimei Investment Ltd (the “ Sponsor ”) into the trust account in connection with extending the timeframe within which the Company must consummate its initial business combination, from $0.033 per Public Share (as defined below) (for each monthly extension) to an amount equal to $150,000 for all outstanding Public Shares (for each monthly extension) (the “ Trust Agreement Amendment Proposal ”); 2. The fifth paragraph of the Notice of Extraordinary General Meeting of Shareholders is hereby amended and restated as follows: The Articles and the Trust Agreement provide that the Company has until 12 months from the closing of its IPO (“ Combination Period ”) to consummate its initial business combination (namely, until December 6, 2024). The Articles and the Trust Agreement also provide that if the board of directors (the “ Board ”) anticipates that we may not be able to consummate our initial business combination within the Combination Period, we may, by resolution of the Board if requested by our Sponsor, extend the Combination Period up to twelve (12) times each for an additional one month (each, a “ Monthly Extension ”) from December 6, 2024 (i.e., 12 months after the consummation of the IPO) up to December 6, 2025 (i.e., 24 months after the consummation of the IPO) subject to the Sponsor depositing additional funds into the trust account (the “ Trust Account ”) established pursuant to the Trust Agreement, in accordance with the terms set out in that agreement and referred to in the Reg

View Full Filing

View this DEFA14A filing on SEC EDGAR